ZLAB - Zai Lab Limited

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
24.72
+3.54 (+16.71%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close21.18
Open21.24
Bid16.56 x 1400
Ask25.00 x 800
Day's Range21.02 - 24.93
52 Week Range14.29 - 27.34
Volume1,189,829
Avg. Volume150,633
Market Cap1.436B
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-1.63
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est44.67
Trade prices are not sourced from all markets
  • GlobeNewswire2 days ago

    Zai Lab Announces Acceptance of NDA Submission of ZEJULA (Niraparib) in Mainland China by the NMPA

    Zai Lab Limited (ZLAB), a Shanghai-based innovative commercial stage biopharmaceutical company, today announced that the China National Medical Products Administration (NMPA) has accepted its New Drug Application (NDA) for ZEJULA (niraparib, or ZL-2306) as a Category 1 drug for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal ovarian cancer who are in a complete or partial response to platinum-based chemotherapy. “The NMPA’s acceptance of our NDA submission for ZEJULA represents a major milestone for Zai Lab as this is our first ever NDA submission in Mainland China,” said Dr. Samantha Du, Founder and Chief Executive Officer of Zai Lab.

  • George Soros Bought These 2 Healthcare Stocks in the Third Quarter
    Motley Fool11 days ago

    George Soros Bought These 2 Healthcare Stocks in the Third Quarter

    The Soros Fund Management bought shares of both Express Scripts and Zai Lab Limited during the third quarter.

  • GlobeNewswire15 days ago

    MacroGenics and Zai Lab Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Margetuximab, MGD013 and TRIDENT™ Molecule in Greater China

    Margetuximab, an immune-optimized anti-HER2 monoclonal antibody currently being evaluated in Phase 3 metastatic breast cancer with anticipated topline results in the first quarter of 2019. Zai Lab obtains regional development and commercialization rights for these programs in mainland China, Hong Kong, Macau and Taiwan.

  • GlobeNewswirelast month

    Zai Lab and Novocure Awarded Deal of the Year

    Zai Lab Limited (ZLAB), a Shanghai-based innovative biopharmaceutical company, and Novocure Limited (NVCR) today announced that they have received the Deal of the Year Award at the 9th Annual BayHelix Awards Lunch Banquet held during the annual BioCentury-BayHelix China Healthcare Summit in Shanghai, China. The annual award recognizes a groundbreaking collaboration, technology transfer, licensing, capital raising, M&A or joint venture that involves a Chinese company in the healthcare sector. In September of this year, Zai Lab and Novocure announced a strategic collaboration and an exclusive license agreement in the field of oncology by which Zai lab would develop and launch Novocure’s Tumor Treating Fields (TTFields) technology, under the brand name Optune®, in Greater China and to collaborate with Novocure in the global development of the product.  TTFields is a cancer therapy that uses electric fields tuned to specific frequencies to disrupt cell division, inhibiting tumor growth and causing affected cancer cells to die.

  • GlobeNewswire2 months ago

    Zai Lab Announces Approval of ZEJULA® (Niraparib) for Patients with Relapsed Ovarian Cancer in Hong Kong

    Zai Lab Limited (ZLAB), a Shanghai-based innovative biopharmaceutical company, today announced that the Hong Kong Department of Health has approved ZEJULA® (niraparib), an oral, once-daily poly (ADP-ribose) polymerase (PARP) inhibitor in Hong Kong for adult patients with platinum-sensitive relapsed high grade serous epithelial ovarian cancer who are in a complete response or partial response (CR or PR) to platinum-based chemotherapy. Unlike other PARP inhibitors approved in Hong Kong, ZEJULA does not require BRCA mutation or other biomarker testing prior to administration.

  • Business Wire2 months ago

    Five Prime Therapeutics and Zai Lab Dosed First Patient in Phase 3, Global Registrational Trial of Bemarituzumab in Front-Line Advanced Gastric and Gastroesophageal Junction Cancers

    Five Prime Therapeutics, Inc. (FPRX), a biotechnology company discovering and developing innovative immuno-oncology protein therapeutics, and Zai Lab Limited (ZLAB), a Shanghai-based innovative biopharmaceutical company, today announced dosing of the first patient in the Phase 3 FIGHT pivotal trial of bemarituzumab (FPA144), an isoform-selective FGF receptor 2b (FGFR2b) antibody, in combination with chemotherapy in patients with previously untreated, advanced gastric cancer (GC) or gastroesophageal junction (GEJ) cancer. The first patient was dosed at a participating investigative site in China on Sept. 28.

  • Chinese Market Opportunity Could Drive Zai Lab’s Revenue Growth
    Market Realist3 months ago

    Chinese Market Opportunity Could Drive Zai Lab’s Revenue Growth

    Headquartered in Shanghai, China, Zai Lab (ZLAB) is focused on the development of therapies in areas such as immunology, oncology, and infectious diseases. The company targets the high unmet demand in the Chinese market in which the incidence rate across multiple oncology indications is significantly higher than in the US market. Zai Lab reported a year-to-date return of -9.8%.

  • GlobeNewswire3 months ago

    Zai Lab Appoints Industry Leader Tao Fu as President & Chief Operating Officer, Expands US Presence

    Zai Lab Limited (ZLAB), a Shanghai-based innovative biopharmaceutical company, today announced the appointment of Tao Fu as President and Chief Operating Officer, effective September 24, 2018. Mr. Fu joins Zai Lab from Portola Pharmaceuticals, where he served as Executive Vice President, Chief Commercial and Business Officer.

  • GlobeNewswire3 months ago

    Zai Lab Presents Results of its Pharmacokinetics (PK) Study for ZL-2306 (niraparib) in Chinese Ovarian Cancer Patients Showing Comparable Profile to non-Chinese Patients at the 21st Annual Meeting of the Chinese Society of Clinical Oncology

    Zai Lab Limited (ZLAB), a Shanghai-based innovative biopharmaceutical company, presented results of its open-label study to evaluate the pharmacokinetic (PK) profile of ZL-2306 (niraparib) made in China in Chinese ovarian cancer patients. Results from the study show comparable PK profile of the Chinese patients administered ZL-2306 to that of patients evaluated in Tesaro’s global PK study. The open-label PK Study enrolled 36 Chinese patients with stage III or IV epithelial ovarian, fallopian tube or primary peritoneal cancer.

  • GlobeNewswire3 months ago

    Zai Lab to Participate in the Leerink Rare Disease & Immuno-Oncology Roundtable

    SHANGHAI, China, Sept. 25, 2018 -- Zai Lab Limited (NASDAQ:ZLAB), a Shanghai-based innovative biopharmaceutical company, today announced that senior management will participate.

  • Business Wire3 months ago

    Novocure and Zai Lab Announce Strategic Collaboration with a License Agreement for Tumor Treating Fields in Greater China

    Novocure (NVCR), a global oncology company developing a proprietary platform technology called Tumor Treating Fields, and Zai Lab (ZLAB), a Shanghai-based innovative biopharmaceutical company, announced today an exclusive license agreement for Tumor Treating Fields, including the brand name Optune, in Greater China and a global strategic development collaboration. This agreement will enable Novocure to access the Chinese market and is intended to accelerate clinical trial enrollment.

  • Here's Why Zai Lab Limited Dropped Today
    Motley Fool3 months ago

    Here's Why Zai Lab Limited Dropped Today

    A secondary offering has investors hitting the sell button.

  • Zai Lab (ZLAB) in Focus: Stock Moves 6.2% Higher
    Zacks4 months ago

    Zai Lab (ZLAB) in Focus: Stock Moves 6.2% Higher

    Zai Lab (ZLAB) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

  • Zai Lab Stock Down, Atopic Dermatitis Candidate Trial Fails
    Zacks4 months ago

    Zai Lab Stock Down, Atopic Dermatitis Candidate Trial Fails

    Shares of Zai Lab (ZLAB) decline following the failure of a phase IIA study on its pipeline candidate, ZL-3101, for the treatment of atopic dermatitis.

  • Reuters4 months ago

    U.S.-listed Chinese biotech Zai Lab plans Hong Kong float -sources

    HONG KONG, Aug 22 (Reuters/IFR) - Zai Lab Ltd is planning a Hong Kong float after its Nasdaq debut last year, in what would be the second U.S.-listed Chinese biotech firm to return to the city following an implementation of new listing rules, sources said. Zai Lab is in talks with advisers for a share sale plan in Hong Kong, which is seeking to establish itself as a financing hub for pre-revenue drug developers, the sources added.

  • Reuters4 months ago

    U.S.-listed Chinese biotech Zai Lab plans Hong Kong float -sources

    HONG KONG, Aug 22 (Reuters/IFR) - Zai Lab Ltd is planning a Hong Kong float after its Nasdaq debut last year, in what would be the second U.S.-listed Chinese biotech firm to return to the city following an implementation of new listing rules, sources said. Zai Lab is in talks with advisers for a share sale plan in Hong Kong, which is seeking to establish itself as a financing hub for pre-revenue drug developers, the sources added.